Clinical Trials for Rectal Cancer

A Phase 1/2, Dose Escalation and Expansion Trial to Evaluate the Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable metastatic colorectal adenocarcinoma that has progressed after, or is intolerant to, at least two systemic therapy lines receive IV tegavivint alone or with unspecified standard-of-care regimens. Tegavivint inhibits Wnt/β-catenin signaling by binding TBL1 proteins and disrupting β-catenin-dependent transcription.

ClinicalTrials.gov ID: NCT07463599

A Pilot Study of Botensilimab and Balstilimab and SBRT in Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with chemorefractory MSS/pMMR metastatic colorectal cancer, 1–5 liver lesions suitable for SBRT, and at least one measurable unirradiated extrahepatic lesion receive liver-directed SBRT plus botensilimab (an Fc-engineered anti-CTLA-4 antibody) and balstilimab (an anti-PD-1 antibody).

ClinicalTrials.gov ID: NCT07128355

A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors harboring specified RAS mutations, ECOG 0–1, generally without acceptable standard systemic options; a newly diagnosed pancreatic ductal adenocarcinoma cohort is also eligible. Patients receive oral ERAS-0015, a pan-RAS molecular glue that disrupts active RAS–effector interactions and inhibits MAPK signaling, alone or with other investigational anticancer agents.

ClinicalTrials.gov ID: NCT06983743

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, microsatellite-stable metastatic colorectal cancer and no prior treatment for metastatic disease receive SAR445877, a PD-1–blocking antibody linked to a modified IL-15 complex, with FOLFOX6. Bevacizumab is included during dose escalation but is not listed in the dose-expansion arm.

ClinicalTrials.gov ID: NCT07500298

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with eligible advanced solid tumors or breast cancer receive arm-specific combinations of evorpacept, an investigational CD47–SIRPα blocker, plus HER2-directed trastuzumab deruxtecan, or zanidatamab, a bispecific HER2 antibody, plus the HER2 kinase inhibitor tucatinib. Molecular and histologic eligibility varies by arm.

ClinicalTrials.gov ID: NCT05868226

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed or refractory advanced solid tumors who have exhausted or are unlikely to benefit from standard therapy receive autologous CRX100, activated immune cells carrying a tumor-selective oncolytic vaccinia virus, alone or with pembrolizumab. Eligible patients need measurable disease and ECOG performance status 0–1.

ClinicalTrials.gov ID: NCT04282044

A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced solid tumors and ECOG 0–1 are eligible for genotype-defined cohorts with KRAS, NRAS, or HRAS mutations; a separate cohort includes RAS–wild-type pancreatic ductal adenocarcinoma. All patients receive oral daraxonrasib (RMC-6236), a multiselective RAS(ON) inhibitor that blocks signaling by active RAS.

ClinicalTrials.gov ID: NCT05379985

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic solid tumors, including renal, prostate, urothelial, liver, lung, colorectal, and head and neck cancers, receive oral zanzalintinib alone or with nivolumab, nivolumab plus ipilimumab, or nivolumab plus relatlimab. Zanzalintinib inhibits VEGFR2, MET, and TAM kinases; the checkpoint inhibitors target PD-1, CTLA-4, and LAG-3, respectively.

ClinicalTrials.gov ID: NCT05176483

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls patients with unresectable or metastatic KRAS G12C-mutant solid tumors, including NSCLC, colorectal cancer, and pancreatic cancer, generally after standard therapy; a cohort includes previously untreated advanced NSCLC. Patients receive olomorasib, an oral inhibitor that binds inactive KRAS G12C, alone or with pembrolizumab, cetuximab, or pembrolizumab plus pemetrexed and platinum chemotherapy, depending on cohort.

ClinicalTrials.gov ID: NCT04956640

An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects with Advanced or Metastatic Solid Tumor Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic EGFR-expressing solid tumors who have progressed on or cannot tolerate established therapies receive weekly intravenous JANX008, a protease-activated, masked EGFR×CD3 T-cell engager designed to activate in the tumor microenvironment. The sponsor has discontinued JANX008 development because of insufficient magnitude and consistency of activity.

ClinicalTrials.gov ID: NCT05783622